A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Status:
Not yet recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
This study will test the safety of a drug called SGN-BB228 in participants with melanoma and
other solid tumors that are hard to treat or have spread through the body. It will also study
the side effects of this drug. A side effect is anything a drug does to the body besides
treating the disease.
This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228
should be given to participants. Part C will use the information from Parts A and B to see if
SGN-BB228 is safe and if it works to treat solid tumor cancers.